[8-K] GLOBUS MEDICAL INC Reports Material Event

Rhea-AI Filing Summary

Globus Medical (GMED) filed an 8-K stating it issued a press release reporting sales and operating results for the three- and nine-month periods ended September 30, 2025. The press release is included as Exhibit 99.1.

The company notes the information under Item 2.02 and the related exhibit are “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.

false0001237831DE00012378312025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025  

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in charter)

DELAWARE		001-35621		04-3744954
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214

(Address of principal executive offices) (Zip Code)

(610) 930-1800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbols	Name of exchange on which registered
Class A Common Stock, par value $.001 per share	GMED	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

‎

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, we issued a press release reporting, among other things, our sales and operating results for the three and nine month period ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 6, 2025
104		The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

‎

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		GLOBUS MEDICAL, INC.
		(Registrant)
Dated:	November 6, 2025	/s/ KYLE KLINE
		Kyle Kline
		Chief Financial Officer
		(Principal Financial Officer)
		Senior Vice President

FAQ

What did Globus Medical (GMED) announce in this 8-K?

It reported that a press release with sales and operating results for the three- and nine-month periods ended September 30, 2025 was issued and furnished as Exhibit 99.1.

Which reporting period does GMED’s press release cover?

The three- and nine-month periods ended September 30, 2025.

How is the information in this 8-K treated legally?

It is furnished under Item 2.02 and not filed for purposes of Section 18 of the Exchange Act.

Where can I find the detailed results mentioned?

In Exhibit 99.1, the press release dated November 6, 2025.

Which form did GMED use for this disclosure?

Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Who signed the 8-K for GMED?

It was signed by Kyle Kline, Chief Financial Officer and Senior Vice President.